Document Detail

A longitudinal assessment of the effect of inhaled fluticasone propionate therapy on adrenal function and growth in young children with asthma.
MedLine Citation:
PMID:  18286548     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Fluticasone proprionate (FP) is increasingly used to treat very young children with asthma. Its safety in terms of effects on the hypothalamic pituitary axis (HPA) and growth in this age group is uncertain. PATIENTS AND METHODS: Eleven children (median (range) age 10 (5.6-24.3) months) presenting with recurrent wheeze and family history of asthma were studied prospectively for a period of 18 months. Children received daily-inhaled FP 250 microg via a spacer device. No other corticosteroid therapy was administered prior to or during the study. A Short Standard Synacthen Test (SST) (125 microg) was performed pretreatment, and after 6 and 18 months. Weight (Wt), height (Ht), and body mass index (BMI) were measured at 3-6 monthly intervals. RESULTS: Fasting early morning and peak cortisol levels remained within the normal reference range with therapy. There were no changes in Ht SDS, whereas both Wt SDS (baseline 0.05 (-2.17 to 0.52) vs. +18 months 0.68 (-0.5 to 1.36) P < 0.02) and BMI SDS (-0.22 (-1.73 to 0.75) vs. 0.86 (0.03 to 1.99) P < 0.005) increased after 18 months of treatment. CONCLUSION: Daily treatment with inhaled FP 250 microg in young children with asthma appears to have no adverse effects on the HPA or on linear growth, however, treatment is associated with increases in body Wt and BMI in young children.
R Iles; R M Williams; R W Williams; A Deeb; R Ross-Russell; C L Acerini
Related Documents :
3918828 - Histamine-induced asthma in children: effects on the ventilation-perfusion relationship.
7658278 - Comparison of adenosine 5'-monophosphate and methacholine for the differentiation of as...
6494608 - Influence of a minimal surgical transection around the trachea on bronchoconstriction i...
12578038 - Validation of the natus co-stat end tidal breath analyzer in children and adults.
17090408 - Soluble endothelial adhesion molecule concentration in patients with aortic coarctation.
22545208 - Functional movement is negatively associated with weight status and positively associat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pediatric pulmonology     Volume:  43     ISSN:  1099-0496     ISO Abbreviation:  Pediatr. Pulmonol.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-03-04     Completed Date:  2008-06-04     Revised Date:  2008-10-22    
Medline Journal Info:
Nlm Unique ID:  8510590     Medline TA:  Pediatr Pulmonol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  354-9     Citation Subset:  IM    
Department of Paediatrics, Addenbrooke's NHS Trust, Cambridge, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Androstadienes / administration & dosage,  adverse effects,  therapeutic use*
Asthma / drug therapy*
Biological Markers / blood
Body Height / drug effects*
Body Mass Index
Body Weight / drug effects*
Bronchodilator Agents / administration & dosage,  adverse effects,  therapeutic use
Child Development / drug effects
Child, Preschool
Cohort Studies
Hydrocortisone / blood
Hypothalamo-Hypophyseal System / drug effects*
Longitudinal Studies
Pituitary-Adrenal System / drug effects*
Prospective Studies
Respiratory Sounds / drug effects
Grant Support
//Wellcome Trust
Reg. No./Substance:
0/Androstadienes; 0/Biological Markers; 0/Bronchodilator Agents; 50-23-7/Hydrocortisone; 90566-53-3/fluticasone
Erratum In:
Pediatr Pulmonol. 2008 Jul;43(7):727-8
Note: Williams, R W [corrected to Williams, R M]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Activation of the ERK pathway in osteoblastic cells, role of gremlin and BMP-2.
Next Document:  Use of balloon-expandable metallic stent in a premature infant with congenital tracheobronchial sten...